AR045720A1 - Derivados de pirrol 2,5 tio y oxo sustituidos como moduladores de receptores hormonales de higado - Google Patents
Derivados de pirrol 2,5 tio y oxo sustituidos como moduladores de receptores hormonales de higadoInfo
- Publication number
- AR045720A1 AR045720A1 ARP040102418A ARP040102418A AR045720A1 AR 045720 A1 AR045720 A1 AR 045720A1 AR P040102418 A ARP040102418 A AR P040102418A AR P040102418 A ARP040102418 A AR P040102418A AR 045720 A1 AR045720 A1 AR 045720A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- phenyl
- group
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Derivados de Pirrol 2,5 tio y oxo sustituidos como moduladores de receptores hormonales de higado. Tratamiento de estados clínicos que incluyen enfermedades cardiovasculares tales omo aterosclerosis; enfermedades inflamatorias, enfermedad de alzheimer, trastornos lipídicos (dislipidemias) asociados o no con la resistencia a la insulina, diabetes de tipo 2 y otra manifestaciones del síndrome metabólico, métodos para su utilización terapéutica y composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula 1 donde R1 se selecciona entre fenil (C1-4) alquilo donde el fenilo se sustituye opcionalmente por (C1-4)alcoxicarbonilo o un grupo de fórmula NRaRb donde Ra y Rb independientemente representan H o (C1-4) alquilo o un grupo de fórmulka NRaRb donde Ra y Rb independientemente representa H o (C1-4) alquilo; o un grupo (C1-6) alquilo el cual se sustituye opcionalmente por uno o más de los siguientes : fluoro, (C1-4)alcoxicarbonilo , (C1-3) alquiltio o (C1-3) alcoxi opcionalmente sustituido por uno o más fluoro; R2 es fenilo; R3 se selecciona entre fenilo, indolilo o benzofuranilo cada uno opcionalmente sustituiddo por uno o más de los siguientes: (C1- 3)alcanoilo, (C1-4) alcoxi opcionalmente sustituido por uno o más fluoreo; ( C1-3) alquiltio; o un grupo de fórmula NRaRb donde Ra Rb independientemente representan H, (C1-3)alquilo o (C1-3) alcanoilo o Ra y Rb junto con el átomo de nitrógeno al cual se encuentran unidos representan morfolino; X es O o S; o una sal o solvarto aceptable para uso farmacéutico de los mismos, o un solvato de dicha sal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045720A1 true AR045720A1 (es) | 2005-11-09 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102418A AR045720A1 (es) | 2003-07-11 | 2004-07-08 | Derivados de pirrol 2,5 tio y oxo sustituidos como moduladores de receptores hormonales de higado |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (es) |
| EP (1) | EP1646625B1 (es) |
| JP (1) | JP2007521313A (es) |
| KR (1) | KR20060034284A (es) |
| CN (1) | CN100478340C (es) |
| AR (1) | AR045720A1 (es) |
| AT (1) | ATE399776T1 (es) |
| AU (1) | AU2004256000B2 (es) |
| BR (1) | BRPI0412479A (es) |
| CA (1) | CA2532068A1 (es) |
| CO (1) | CO5640134A2 (es) |
| DE (1) | DE602004014772D1 (es) |
| ES (1) | ES2308205T3 (es) |
| GB (1) | GB0316237D0 (es) |
| HK (1) | HK1088318A1 (es) |
| IL (1) | IL172759A0 (es) |
| IS (1) | IS8291A (es) |
| MX (1) | MXPA06000447A (es) |
| NO (1) | NO20060080L (es) |
| RU (1) | RU2006102129A (es) |
| SA (1) | SA04250203B1 (es) |
| TW (1) | TW200507836A (es) |
| UA (1) | UA82108C2 (es) |
| UY (1) | UY28407A1 (es) |
| WO (1) | WO2005005416A1 (es) |
| ZA (1) | ZA200600229B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2592771A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| WO2007002654A2 (en) * | 2005-06-28 | 2007-01-04 | Daiichi Sankyo Company, Limited. | Lxr ligand testing method |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| WO2008103818A1 (en) * | 2007-02-21 | 2008-08-28 | University Of Louisville Research Foundation | Therapeutic cotinine compositions |
| PT2868315T (pt) | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| WO2009097443A2 (en) * | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| PE20110570A1 (es) | 2008-07-01 | 2011-08-26 | Genentech Inc | Heterociclos biciclicos sustituidos |
| US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| JP2023509845A (ja) | 2019-12-13 | 2023-03-10 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2234300T3 (es) * | 1998-10-08 | 2005-06-16 | Smithkline Beecham Plc | 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa. |
| CA2377999A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc | Compositions and methods for raising hdl cholesterol levels |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en not_active Expired - Lifetime
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en active IP Right Grant
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Application Discontinuation
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
- 2006-08-07 HK HK06108722.2A patent/HK1088318A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200507836A (en) | 2005-03-01 |
| ZA200600229B (en) | 2007-04-25 |
| UY28407A1 (es) | 2005-02-28 |
| NO20060080L (no) | 2006-02-08 |
| SA04250203B1 (ar) | 2008-02-25 |
| MXPA06000447A (es) | 2006-04-07 |
| CO5640134A2 (es) | 2006-05-31 |
| GB0316237D0 (en) | 2003-08-13 |
| BRPI0412479A (pt) | 2006-09-19 |
| ES2308205T3 (es) | 2008-12-01 |
| EP1646625A1 (en) | 2006-04-19 |
| IL172759A0 (en) | 2006-04-10 |
| CN1820003A (zh) | 2006-08-16 |
| EP1646625B1 (en) | 2008-07-02 |
| ATE399776T1 (de) | 2008-07-15 |
| RU2006102129A (ru) | 2006-08-27 |
| CN100478340C (zh) | 2009-04-15 |
| UA82108C2 (uk) | 2008-03-11 |
| CA2532068A1 (en) | 2005-01-20 |
| DE602004014772D1 (de) | 2008-08-14 |
| WO2005005416A1 (en) | 2005-01-20 |
| JP2007521313A (ja) | 2007-08-02 |
| HK1088318A1 (en) | 2006-11-03 |
| US20060189663A1 (en) | 2006-08-24 |
| AU2004256000A1 (en) | 2005-01-20 |
| KR20060034284A (ko) | 2006-04-21 |
| AU2004256000B2 (en) | 2007-07-26 |
| IS8291A (is) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045720A1 (es) | Derivados de pirrol 2,5 tio y oxo sustituidos como moduladores de receptores hormonales de higado | |
| AR045721A1 (es) | Derivados de pirrol 2,5 diona como moduladores de receptores hormonales de higado | |
| AR056560A1 (es) | Pirrolopiridinonas como moduladores cb1 | |
| AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| AR029919A1 (es) | Fenil sulfamoil carboxamidas sustituidas con uracilo | |
| NI201000022A (es) | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| PE20060921A1 (es) | Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR069207A1 (es) | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| AR071857A1 (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR092684A1 (es) | Compuestos de sulfonamida sustituidos | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |